From: Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective
 | Prophylaxis | No Prophylaxis | Difference |
---|---|---|---|
Prophylaxis | 3664 EUR | 0 EUR | 3664 EUR |
RSV-hospitalizations | 5171 EUR | 10,315 EUR | â5145 EUR |
âGeneral | 499 EUR | 691 EUR | ââ191 EUR |
âICU | 286 EUR | 1279 EUR | ââ993 EUR |
âSupplemental oxygen | 96 EUR | 349 EUR | ââ253 EUR |
âMechanical ventilation | 23 EUR | 188 EUR | ââ165 EUR |
âCPAP | 400 EUR | 727 EUR | ââ327 EUR |
âECMO | 3744 EUR | 6806 EUR | ââ3063 EUR |
âHotel nights | 55 EUR | 124 EUR | â69 EUR |
âProductivity losses | 68 EUR | 152 EUR | â84 EUR |
Heart complications | 2544 EUR | 4626 EUR | â2082 EUR |
Asthma | 1470 EUR | 1739 EUR | ââ270 EUR |
Total costs | 12,848 EUR | 16,681 EUR | â3833 EUR |
Total QALYs | 17.82 | 17.75 | 0.06 |
Total LY | 20.15 | 20.12 | 0.03 |
ICER (QALY) | Â | Â | DOMINANCE |
ICER (LYG) | Â | Â | DOMINANCE |